Healthcare Nov 19, 2020 09:57 AM (GMT+8) · EqualOcean
Heyuan Biotechnology (Tianjin) Co., Ltd. announced that it completed a new round of financing of 450 million yuan, EUROHEALTH news on Monday. This round of financing is led by investment and investment by China. New investors such as Tianchuang capital, Ruisheng investment, Jizi wealth and rural finance capital are following the investment. The existing investors of the company, Jiadao Fanghua, ETP, Kaixin biology, Daxie pengchuang and daotong, continue to participate in the follow-up investment. This financing will accelerate the clinical transformation and commercialization process of cnct19 cell injection, which is the target of CD19, and promote the development of the following two target car-t products, til products and other pipeline products. According to the data of the State Drug Administration, cnct19 cell injection officially obtained two ind licenses on November 29 last year, which are two indications for the treatment of relapse or refractory invasive B-cell non Hodgkin's lymphoma and the treatment of recurrent or refractory acute lymphoblastic leukemia. Among them, the clinical trial of relapse or refractory invasive B-cell non Hodgkin lymphoma has entered the stage II of registered clinical. The registered clinical phase II trial for the treatment of relapse or refractory acute lymphoblastic leukemia is also about to start the group.

This text is a result of machine translation.